arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CytomX Therapeutics, Inc.

CTMX
$2.12 ▼ -0.23 (-10.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

CytomX Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $292.4M
Dividend Yield —
Revenue Growth -44.8% ↘
Op. Margin -29.3% ↘
ROIC -22.9% ↗
FCF / Share $-0.55 ↗
Trailing P/E —
Price / Book 3.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$76.20M
↓ -44.8% —
Net Income Profit after all expenses
$-17.37M
↓ -154.5% —
Operating Margin Operating profit as % of sales
-29.3%
↓ -262.2% 8th
FCF / Share Free cash flow per share
$-0.55
↑ +46.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
7
Returns ↑
29
Cash Quality ↑
94

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 51 quarters